Thomas Guttuso, MD
Neurology · Buffalo, NYNPI 1134192404
Payments from drug & device makers
Across 78 payments — averaging $2510.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$172K
- Acorda Therapeutics, Inc$17K
- Biogen$6K
- MDD US Operations, LLC$278
- AbbVie$179
- Teva Pharmaceuticals USA, Inc.$166
- plus $446 from 8 others
What the payments were for
- Speaking & faculty fees$15,70086%
- Travel & lodging$8845%
- Food & beverage$1,7029%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 8 | $171,866 |
| Acorda Therapeutics, Inc | 19 | $17,228 |
| Biogen | 2 | $5,671 |
| MDD US Operations, LLC | 16 | $278 |
| AbbVie | 7 | $179 |
| Teva Pharmaceuticals USA, Inc. | 8 | $166 |
| Medtronic | 1 | $158 |
| Neurocrine Biosciences, Inc. | 4 | $82 |
| Supernus Pharmaceuticals, Inc. | 3 | $72 |
| UCB, Inc. | 2 | $44 |
| Greenwich Biosciences, Inc. | 1 | $31 |
| Eisai Inc. | 1 | $30 |
| GE HealthCare | 2 | $18 |
| Travere Therapeutics, Inc. | 4 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INBRIJA$16,738
- PERCEPT PC BRAINSENSE$158
How this compares
$195,834 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $82,985 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 780 | $63,473 |
| Rasagiline Mesylate | 129 | $28,778 |
| RytaryCarbidopa/Levodopa | 12 | $24,111 |
| Selegiline Hcl | 92 | $10,451 |
| AmantadineAmantadine Hcl | 144 | $5,584 |
| Rivastigmine | 17 | $4,540 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 54 | $3,448 |
| Fludrocortisone Acetate | 56 | $3,175 |
| Primidone | 84 | $3,079 |
| Gabapentin | 166 | $2,370 |
| Propranolol Hcl ErPropranolol Hcl | 49 | $2,180 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 72 | $2,068 |
| Midodrine Hcl | 27 | $1,614 |
| Donepezil Hcl | 133 | $1,536 |
Paid to pharmacies, not to this prescriber.
Other neurology in Buffalo
- Kinga SzigetiBuffalo$3M
- Bianca Weinstock GuttmanBuffalo$1.4M
- Gil WolfeBuffalo$829K
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.